Premature coronary artery disease and early stage chronic kidney disease.

Although randomized studies in dialysis patients found no reduction in death, non-fatal MI or stroke following the reduction of LDL the large Study of Heart and Renal Protection (SHARP), showed that the combination of simvastatin and ezetimibe caused a highly significant 17% reduction in atherosclerotic events. 25 , 26 In SHARP the effects of statins on events was similar in both dialysis and non-dialysis patients but a meta-analysis showed that the reduction in major vascular events fell as the eGFR decreased, suggesting that subjects with early stage CKD gain mos

also in 132,142 other papers